Search academic texts

Information × Registration Number 0224U002225, 0121U111542 , R & D reports Title Determination of hematologic disorders and disorders of hemostasis that developed as a result of COVID-19 popup.stage_title Head Horiainova Nadiia V., д.мед.н. Registration Date 08-02-2024 Organization State Institution "Institute of Hematology and Transfusiology of the National Academy of Medical Sciences of Ukraine" popup.description2  Object: people who have been infected with COVID-19; their peripheral blood (indicators of complete blood count, iron metabolism and coagulogram). Methods: clinical; cytological; biochemical; immunological; instrumental, mathematical and statistical. It has been established that the most common hematologic disorders occurring in patients after coronavirus disease are immune cytopenias (55%), anemia of chronic disease (13%) and hyperferritinemia (13%). In 85.7% of patients with mild to moderate thrombocytopenia, platelet counts normalize within 1-9 months; in 14.3%, platelet counts decrease with the need for therapy. Immune thrombocytopenia (ITP) may occur regardless of the severity of COVID-19 and can be seen immediately or after recovery. Standard ITP therapy has been shown to be effective in achieving complete and prolonged clinical and hematologic remission in most patients. The use of glucocorticoid hormones in patients with COVID-19-associated secondary autoimmune hemolytic anemia ensures complete long-term remission. Iron metabolism disorders may indicate a prolonged inflammatory process or signal the onset of other pathologies associated with post-COVID syndrome. The neutrophil-lymphocyte ratio correlates with the severity of COVID-19; prolonged persistence of its elevated level may be a predictor of post-COVID syndrome. The most common hemostatic disorders in patients after coronavirus disease are thrombosis and hypercoagulation syndrome. Changes in the hemostatic system detected during acute COVID-19 can persist for 12 months or more after recovery. Prothrombotic changes are more common than hypocoagulable changes and can lead to life-threatening thrombotic complications in patients with COVID-19. Comorbidities and age over 75 were associated with an increased risk of severe COVID-19 when there was no association with CLL-directed treatment. The absence of COVID-19 vaccination is a risk factor for severe disease. Medical and social effect. Medicine. Product Description popup.authors Anoshina Militina Yu. Basova Olha V. Horiainova Nadiia V. Kyselova Olena A. Kubarova Valentyna O. Kuiavovych Bohdana M. Starodub Halyna S. Tretyak Nataliia M. Yahovdik Maryna V. popup.nrat_date 2024-02-08 Close